TFF Pharmaceuticals, Catalent: manufacturing agreement
TFF Pharmaceuticals and Catalent have announced a collaborative agreement centered on generation, testing and manufacture of dry-powder formulations for a range of biotherapeutics, using TFF’s thin-film freezing technology. Catalent will provide scale-up expertise and manufacturing capabilities to TFF Pharmaceuticals as its preferred development and manufacturing partner, and Catalent will have the right to offer its customers access to the TFF technology.
“Catalent is widely known as a global leader in enabling pharmaceutical development and manufacturing and has distinguished itself by demonstrating cutting-edge expertise across multiple modalities and innovative projects,” said Glenn Mattes, CEO of TFF Pharmaceuticals. “This strategic collaboration significantly expands our access to manufacturing capabilities and provides scalability for our technology, while simultaneously affording us the opportunity to build our portfolio of technology licensing partnerships.”